Vla insane, page-18

Yeah, I think overall he results were pretty good. A study comparing Keytruda vs. Opdivo came out a day or two ago in advanced melanoma and the irPFS, and OS of Keytruda compared pretty well to these early results from the CALM trial. The key though is going to be combination therapy between a checkpoint inhibitor and CAVATAK, since CAVATAK has essentially no adverse effects and works very well synergistically, at least in the preclinical murine models that VLA has tested so far, while combination therapies combining Keytruda and Opdivo were also tested and while they had good efficacy, there were a tremendous amount of side effects, >80% of the patients had Grade 3 and 4 serious adverse effects.

So... news was great, VLA still has plenty of cash, and most of the trials except MTCI should be done by end of year, the price should definitely go up from here.